Funding

[Funding alert] Norway-based Medical Device Company CardioMech Secures $13M in Funding

Jan 3, 2024 | By Startup Rise EU

Norway-based Medical Device Company CardioMech Secures $13M in Funding. CardioMech received strong financial support from existing and new investors, including a non-disclosed strategic investor.

Norway-based Medical Device Company CardioMech Secures $13M in Funding. CardioMech received strong financial support from existing and new investors, including a non-disclosed strategic investor.

The heavily oversubscribed round further demonstrates investors' expectations that Chordal Repair may be a first-line therapy for Degenerative Mitral Regurgitation patients and, particularly for CardioMech, confidence that CardioMech can lead the market.

Read also - London-based Olsam Group Acquired Dwarfs

The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible.

RECOMMENDED FOR YOU

recomd
Funding
[Funding alert] UK-based Pimberly Secures £4Million in Funding
Startup Rise EU
Feb 27, 2024
recomd
Funding
Zeliq funding news – Paris-based Zeliq Raises €9.2 Million in Seed Funding
Startup Rise EU
Jun 11, 2024
recomd
Funding
[Funding alert] British Biotech FA Bio Raises €6.1 Million in Funding
Startup Rise EU
Jan 9, 2024

Rick Nehm, President, CEO and Chairman of the Board of CardioMech said, "I am thrilled to continue building on a successful long-term collaboration with our existing investors in the development of this technology, as well as to partner with new individual investors that truly believe in this team and this technology, We are working together to achieve our objective to significantly improve the standard of care for the millions of patients suffering from degenerative mitral regurgitation."

Jacob Bergsland, MD, Founder of CardioMech said, "There is a significant need for a less-invasive technology that can eliminate mitral regurgitation in younger and healthier patients and Norwegian- born CardioMech is developing a category-defining technology that may benefit patients suffering from mitral regurgitation around the world, CardioMech has the right technology, the right team, the right partners in the right market and we are excited to develop this profound technology."

About CardioMech

CardioMech AS, a privately held company, is developing its transcatheter mitral valve chordal repair technology. Caution: Investigational device. Limited by law to investigational use.

Read also - GLORY to Acquire Flooid

Recommended Stories for You

story
Funding

[Funding alert] Switzerland-based Squid Secures $4Million in Funding

Startup Rise EU Feb 1, 2024

story
Funding

[Funding alert] London-based Saas company AI Build Raises $8.5M Series A Round Funding

Startup Rise EU Oct 19, 2023

story
Funding

Alpine Space Ventures funding news – Munich-based Alpine Space Ventures Secures €170 Million in Funding

Startup Rise EU Jul 12, 2024

story
Funding

[Funding alert] Berlin-based BlueLayer Secures €9.2 Million in Seed & Pre-Seed Funding

Startup Rise EU Jan 31, 2024

story
Funding

[Funidng alert] UK-based Contollo Group Secures an Investment from NorthEdge

Startup Rise EU Feb 17, 2024

story
Funding

[Funding alert] Stockholm-based Alrik Secures €1Million in Seed Funding

Startup Rise EU Apr 3, 2024